Disease · MONDO_0005304
biliary tract neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. biliary tract neoplasm. Diseases, record MONDO_0005304. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005304
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
biliary tract neoplasm (disease), biliary tree neoplasm, biliary tree neoplasm (disease), biliary tree tumor, biliary tree tumour, neoplasm of biliary tree, neoplasm of extrahepatic bile ducts, tumor of biliary tree, tumour of biliary tree
- Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ZANIDATAMAB | CHEMBL4650256 | Antibody | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ADEBRELIMAB | CHEMBL4297828 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MECAPEGFILGRASTIM | CHEMBL5095279 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SOVATELITIDE | CHEMBL3188091 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 1 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VANDETANIB | CHEMBL24828 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets55
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ERBB2 | Epidermal growth factor receptor | 2 | Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor | Approval | https://conductscience.org/library/genes/2064 | Drugs and targets |
| TYMS | Thymidylate synthase | 2 | Thymidylate synthase inhibitor | Phase 2 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 1 | Epidermal growth factor receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| EPHA1 | Ephrin receptor | 1 | Ephrin receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/2041 | Drugs and targets |
| EPHA10 | Ephrin receptor | 1 | Ephrin receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/284656 | Drugs and targets |
| EPHA2 | Ephrin receptor | 1 | Ephrin receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/1969 | Drugs and targets |
| EPHA3 | Ephrin receptor | 1 | Ephrin receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/2042 | Drugs and targets |
| EPHA4 | Ephrin receptor | 1 | Ephrin receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/2043 | Drugs and targets |
| EPHA5 | Ephrin receptor | 1 | Ephrin receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/2044 | Drugs and targets |
1 to 10 of 55
See all 55 targetsTrials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01661114 | A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers | Phase 2 | 39 | 2016-02-04 | Pancreatic Cancer, Biliary Cancer | CISPLATIN, FLUOROURACIL, GEMCITABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00626158 | Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers | Phase 1 | 45 | Pancreatic Cancer, Biliary Cancer | CAPECITABINE, GEMCITABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01773785 | Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer | Phase 2 | 30 | Biliary Cancer | DOCETAXEL, SOVATELITIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06037655 | Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC | Phase 2 | 30 | Biliary Tract Neoplasms | ADEBRELIMAB, CISPLATIN, GEMCITABINE, MECAPEGFILGRASTIM | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00551096 | Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors | Phase 1 | 23 | Malignant Solid Tumour, Biliary Cancer, Pancreatic Cancer | CAPECITABINE, GEMCITABINE, VANDETANIB | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 26715573 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005304
GET https://conductscience.org/api/diseases/v1/MONDO_0005304/targets?page=2